CCMU
JBIO

Cheyne Capital Management (UK)’s Jade Biosciences JBIO Stock Holding History

Cheyne Capital Management (UK)’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-541
Closed -$555K – 26
2022
Q4 		$555K Buy
+541
New +$393K 0.97% 36

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Cheyne Capital Management (UK)'s JBIO Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Jade Biosciences (JBIO) in Q1 2023, closing a stake of 541 shares — an estimated $555K sold.

Cheyne Capital Management (UK) first reported a position in JBIO in Q4 2022 and held it in 1 quarter. The position peaked at $555K in Q4 2022. 64 funds tracked by Wall St. Rank hold JBIO as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Jade Biosciences position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 541 Jade Biosciences shares in Q1 2023, an estimated $555K.
  • Cheyne Capital Management (UK) first reported a position in Jade Biosciences in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Jade Biosciences position peaked at $555K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.